Endostar Combination With Chemotherapy for the Metastatic Nasopharyngeal Carcinoma

University of Chinese Academy Sciences

Status and phase

Unknown

Phase 2

Conditions

Nasopharyngeal Carcinoma

Treatments

Drug: endostatin

Study type

Interventional

Funder types

Other

Identifiers

NCT01612286

ZhejaingCH-npc-02

Details and patient eligibility

About

The investigators designed this study to evaluate the efficiency and the acute toxicities of recombinant human endostatin (endostar) combined with chemotherapy in the metastatic nasopharyngeal carcinoma (NPC).

Full description

To evaluate the progression free survival (PFS), overall survival (OS), Acute adverse reaction of recombinant human endostatin (endostar) combined with chemotherapy to the metastatic nasopharyngeal carcinoma (NPC).

Enrollment

30 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Diagnosed metastatic NPC patient who have received radiotherapy or chemoradiotherapy with an at least 6 months interval
Have measurable lesions
No dysfunction of the major organs
Can understand this study and give a signed informed consent certificates
without a history of allergic reaction to the biological agents

Exclusion criteria

Pregnant or lactating women; Women of child-bearing age without contraception
with a Serious infection or dysfunction of the major organs
have taken other antitumor drugs during the period of 30 days ahead of this clinical trial
allergic to the Escherichia coli preparations
Cann't understand this study and give a signed informed consent certificates